Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance Among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections

Ryan K. Shields, Brian A. Potoski, Ghady Haidar, Binghua Hao, Yohei Doi, Liang Chen, Ellen G. Press, Barry N. Kreiswirth, Cornelius J. Clancy, M. Hong Nguyen

Research output: Contribution to journalArticle

167 Citations (Scopus)

Abstract

Thirty-seven carbapenem-resistant Enterobacteriaceae (CRE)-infected patients were treated with ceftazidime-avibactam. Clinical success and survival rates at 30 days were 59% (22/37) and 76% (28/37), respectively. In 23% (5/22) of clinical successes, CRE infections recurred within 90 days. Microbiologic failure rate was 27% (10/37). Ceftazidime-avibactam resistance was detected in 30% (3/10) of microbiologic failures.

Original languageEnglish
Pages (from-to)1615-1618
Number of pages4
JournalClinical infectious diseases : an official publication of the Infectious Diseases Society of America
Volume63
Issue number12
DOIs
Publication statusPublished - 15-12-2016
Externally publishedYes

    Fingerprint

All Science Journal Classification (ASJC) codes

  • Microbiology (medical)
  • Infectious Diseases

Cite this